Godavari Biorefineries Ltd reported a net loss of ₹19.3 crore for the quarter ended June 30, 2026 (Q1 FY27), widening from a loss of ₹16.0 crore in the same period last year. The deterioration in profitability occurred despite a year-on-year increase in revenue from operations to ₹557.9 crore from ₹533.2 crore, highlighting significant margin pressure across key segments. Total income rose 4.9% to ₹559.9 crore, but this growth was insufficient to offset operational challenges and rising inventory costs.

The Board of Directors approved the unaudited financial results at its meeting held on August 05, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The press release was submitted to the National Stock Exchange of India Limited and BSE Limited on August 06, 2026. Manoj Jain, Company Secretary & Compliance Officer, signed off on the disclosure.

Financial Performance

Revenue from operations for the quarter came in at ₹557.9 crore, compared to ₹533.2 crore in the prior year quarter. EBITDA contracted sharply to ₹2.6 crore from ₹6.5 crore in the same period last year, representing a decline of 60.5%. The EBITDA margin narrowed to 0.5% from 1.2% year-on-year. This represents a significant decline from the ₹92.1 crore EBITDA recorded in Q4 FY26. Gross profit decreased by 1.5% to ₹100.9 crore, with gross margin slipping to 18.0% from 19.2%. Finance costs declined to ₹13.9 crore from ₹15.3 crore, but this reduction was not enough to mitigate the operating loss.

Segment Dynamics

The bio-based chemicals segment emerged as a bright spot, delivering 53% EBITDA growth year-on-year. Its EBITDA margin expanded to 11.4% from 8.9% in Q1 FY26, reflecting benefits from debottlenecking initiatives completed in FY26 and a focus on higher-value specialty products. Samir Somaiya, Chairman & Managing Director, attributed this to robust revenue growth and healthy margin expansion within the division. Revenue from this segment grew 19.8% YoY to ₹168.7 crore.

Conversely, the ethanol segment's contribution to revenue mix shifted significantly. In Q1 FY27, ethanol accounted for 28% of revenue, down from 39% in Q1 FY26. Meanwhile, sugar and cogeneration saw its share rise to 40% from 33%. Bio-based chemicals maintained a steady 30% share, up slightly from 26%. The sugar and cogeneration segment reported an EBITDA loss of ₹14.6 crore, compared to a loss of ₹4.5 crore in Q1 FY26, driven by lower realizations despite improved sugar prices.

Operational Milestones

The company commissioned a 200 KLPD grain-based distillery at Sameerwadi during the quarter. This addition increases Godavari Biorefineries' total ethanol capacity to 800 KLPD, enhancing feedstock flexibility and operational resilience. Management stated this investment strengthens the ability to optimize operations across varying market conditions. The company is also exploring an additional 160 KLPD of fungible capacity to reach 360 KLPD within the existing limit to mitigate climate risks.

In R&D developments, the company secured an Indian patent for a cost-effective process to manufacture branched alcohols. Additionally, a Japanese patent was granted for a novel anti-cancer molecule. The company filed an application with the CDSCO for preliminary efficacy trials for its lead novel anti-cancer molecule MSP008-22 targeting Triple Negative Breast Cancer, with trials expected to commence in Q3 FY27, subject to regulatory approvals.

What the Numbers Show

The divergence between top-line growth and bottom-line performance is stark. While revenue grew year-on-year to ₹557.9 crore, EBITDA fell sharply to ₹2.6 crore from ₹6.5 crore, with the EBITDA margin compressing to 0.5% from 1.2%. This suggests that revenue growth was not accretive to operating margins, likely due to lower margins in the larger sugar and ethanol segments offsetting the high-margin performance of bio-based chemicals. The widening net loss indicates that fixed costs and finance charges remain significant burdens despite the reduction in interest expenses.

Godavari Biorefineries Ltd shareholders have approved the re-appointment of Mr Nitin Mehta and Dr Sangeeta Srivastava as directors through a postal ballot process. The resolutions sought to re-appoint Mr Nitin Mehta as an Independent Director for a period of five years commencing from July 1, 2026, and Dr Sangeeta Srivastava as a Whole Time Director designated as an Executive Director for a period of three years commencing from August 1, 2026. This decision ensures continuity in the company's leadership structure as it moves forward with its operational strategies.

The remote e-voting facility was open from 9:00 a.m. (IST) on Friday, May 29, 2026, until 5:00 p.m. (IST) on Sunday, June 28, 2026. A total of 89,597 shareholders were eligible to vote as of the record date of Friday, May 15, 2026. The voting process was scrutinized by Tushar Shridharani, a Practicing Company Secretary from Tushar Shridharani & Associates LLP, who was appointed by the Board on May 22, 2026.

Voting Results

Both resolutions were classified as special resolutions and required approval from members. The scrutinizer's report detailed the voting patterns across different shareholder categories, including Promoter and Promoter Group, Public Institutions, and Public Non-Institutions. The results indicated strong support from the promoter group and public institutions.

For the re-appointment of Mr Nitin Mehta, the total number of votes polled stood at 37,958,281, representing 74.17% of the total outstanding shares. The resolution passed with 99.99% of the votes polled in favour. Similarly, the resolution for Dr Sangeeta Srivastava saw 37,958,131 votes polled, accounting for 74.17% of the outstanding shares, with 99.99% of the votes cast in favour.

Scrutinizer's Report

Tushar Shridharani & Associates LLP confirmed that the postal ballot notice was sent in compliance with the Companies Act, 2013, and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report noted that the e-voting module was disabled by NSDL, the service provider, upon the expiry of the voting period. The scrutinizer validated the votes and declared the resolutions passed.

The detailed voting results show that the Promoter and Promoter Group cast 32,400,110 votes in favour of both resolutions, with zero votes against. Public Institutions cast 4,995,317 votes in favour, while Public Non-Institutions cast 560,113 and 560,092 votes in favour for the first and second resolutions, respectively. The company has hosted the full report on its website.